VBY 376

Drug Profile

VBY 376

Alternative Names: VBY-376

Latest Information Update: 18 Apr 2016

Price : $50

At a glance

  • Originator Virobay
  • Class Antivirals; Small molecules
  • Mechanism of Action Cathepsin B inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Discontinued Hepatitis C

Most Recent Events

  • 18 Apr 2016 Phase-I clinical trials in Non-alcoholic steatohepatitis in USA (PO)
  • 18 Apr 2016 VBY 376 is still in phase I trials for Hepatic fibrosis in USA
  • 21 Mar 2013 Phase-I clinical trials in Hepatic fibrosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top